Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Options Market Activity and Sentiment Shift for Goldman Sachs Group Inc

Elaine Mendonca by Elaine Mendonca
March 14, 2024
in Breaking News
0
Finance_ Chart up
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Recent options market activity for Goldman Sachs Group Inc. (NYSE: GS) on March 14, 2024, has seen a shift in sentiment from deep-pocketed investors, with a noticeable increase in options trading. This significant movement suggests a potential major development on the horizon.

Approximately 36% of investors are feeling bullish about GS, while 63% are taking a bearish stance, focusing on a price range between $340.0 and $430.0 over the past three months.

In the last month, there have been several notable options trades for GS, including both calls and puts. For instance, a bearish call trade expiring on 07/19/24 at a strike price of $430.00 had a total trade price of $234.0K and an open interest of 90. Additionally, a bearish call sweep trade expiring on 03/15/24 at a strike price of $375.00 had a total trade price of $76.4K with an open interest of 807.

Currently, GS has a trading volume of 576,634, with a stock price of $395.24, displaying signs of potential overbought conditions based on RSI indicators. Analysts have set an average target price of $430.0 for GS, with varying ratings from different experts.

Options trading for GS carries higher risks but also presents opportunities for increased profits. Traders can manage these risks through ongoing education, strategic adjustments, utilizing indicators, and staying informed about market dynamics.

Goldman Sachs Stock Holds Strong Despite Minor Drop: Potential Investment Opportunity Ahead

On March 14, 2024, Goldman Sachs (GS) stock experienced a slight decrease in value, closing at $390.77, representing a 0.82% drop from the previous day’s closing price. Despite this decrease, GS is still trading near the top of its 52-week range and above its 200-day simple moving average, indicating strong performance over the long term.

Investors may be keeping a close eye on GS stock as it continues to show resilience in the face of market fluctuations. The company’s strong performance over the long term suggests that GS may be a solid investment option for those looking for stability and potential growth.

It will be interesting to see how GS stock performs in the coming days and weeks, as investors react to market trends and company news. With its current position near the top of its 52-week range, GS may continue to be a strong contender in the financial sector.

Goldman Sachs (GS) Stock Performance Analysis: Revenue Up, Net Income Down – March 14, 2024

Goldman Sachs (GS) stock performance on March 14, 2024, saw some interesting trends based on the latest financial data. According to CNN Money, GS reported total revenue of $108.69 billion for the past year, with a quarterly revenue of $29.12 billion. This represents a 61.6% increase in total revenue since last year, while revenue held flat since the last quarter.

In terms of net income, GS reported a total of $8.52 billion for the past year, with a quarterly net income of $2.01 billion. This shows a 24.38% decrease in net income since last year, while net income held flat since the last quarter.

Earnings per share (EPS) for GS were reported at $22.87 for the past year, with a quarterly EPS of $5.48. This represents a 23.93% decrease in EPS since last year, while EPS held flat since the last quarter.

Overall, the financial data for GS on March 14, 2024, shows a mixed performance. While total revenue saw a significant increase since last year, net income and EPS both experienced decreases. It will be interesting to see how these trends continue in the coming quarters and how they will impact GS stock performance in the future. Investors will need to closely monitor these financial indicators to make informed decisions about their investments in GS.

Tags: GS
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
GD stock news

Analyst Maintains InLine Rating on Globe Life Amid DOJ Investigation

Biotechnology Stock Market Today (1)

Presto Automations Stock Surges with Direct Offering Mixed Analyst Ratings for 2024

Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands

Navigating the Rollercoaster MicroStrategy Stock and Bitcoin Reserves

Recommended

Marvell Technology Stock

Marvell Technology Emerges as Key Player in AI Infrastructure Boom

1 month ago
Novo Nordisk Stock

Danish Pharma Giant Novo Nordisk Faces Diverging Analyst Views

1 month ago
Finance_Investment (5)

Anticipation Builds as FirstService Prepares to Release Quarterly Earnings Report

2 years ago
Viking Therapeutics Stock

Acquisition Speculation Fuels Viking Therapeutics Stock Surge

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

DuPont Faces Critical Test as Quarterly Results Loom

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

Trending

BioNTech Stock
Analysis

BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise

by Andreas Sommer
November 6, 2025
0

BioNTech presents investors with a complex financial picture marked by contradictory signals. The German biotech firm reported...

Illumina Stock

China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally

November 6, 2025
Iovance Stock

Iovance Faces Critical Test as Q3 Earnings Approach

November 6, 2025
DuPont de Nemours Stock

DuPont Faces Critical Test as Quarterly Results Loom

November 6, 2025
Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise
  • China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally
  • Iovance Faces Critical Test as Q3 Earnings Approach

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com